Neuronetics Inc 2026年季度报告

FORM10-Q (Mark One) NEURONETICS, INC. (Exact name of registrant as specified in its charter) Not applicable. (Former name, former address and former fiscalyear, if changed since last report) Securities registered pursuant to Section12(b)of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of theSecurities Exchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant wasrequired to file such reports), and (2)has been subject to such filing requirements for the past 90days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12months (or for suchshorter period that the registrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, asmaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “acceleratedfiler,” “smaller reporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act. Large acceleratedfiler☐Accelerated filerNon-accelerated filer☒Smaller reporting companyEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transitionperiod for complying with any new or revised financial accounting standards provided pursuant to Section13(a)of theExchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes☐No☒ There were 76,197,222 shares of the registrant’s common stock outstanding as of August 5, 2026. NEURONETICS, INC. Quarterly Report onForm10-Q for the quarterly period ended June30,2026 Table of Contents PART I – FINANCIAL INFORMATION Item 1.Financial Statements.3Consolidated Balance Sheets as of June 30, 2026 and December 31, 20253Consolidated Statements of Operations for the Three and Six Monthsended June 30, 2026 and 20254Consolidated Statements of Changes in Equity for the Three and SixMonths ended June 30, 2026 and 20255Consolidated Statements of Cash Flows for the Six Months ended June30, 2026 and 20256Notes to Interim Consolidated Financial Statements7Item 2.Management’s Discussion and Analysis of Financial Condition andResults of Operations.27Item 3.Quantitative and Qualitative Disclosures About Market Risk.37Item 4.Controls and Procedures.38PART II – OTHER INFORMATIONItem 1.Legal Proceedings.39Item 1A.Risk Factors.39Item 2.Unregistered Sales of Equity Securities and Use of Proceeds.39Item 3.Defaults Upon Senior Securities.39Item 4.Mine Safety Disclosures.39Item 5.Other Information.39Item 6.Exhibits.40SIGNATURES43 PARTI- FINANCIAL INFORMATION The accompanying notes are an integral part of these unaudited interim consolidated financialstatements. NEURONETICS,INC.Consolidated Statements of Operations(Unaudited; In thousands, except per share data) NEURONETICS,INC.Consolidated Statements of Changes in Equity(Unaudited; In thousands) NEURONETICS,INC.Consolidated Statements of Cash Flows(Unaudited; In thousands) NEURONETICS,INC.Notesto Interim Consolidated Financial Statements(Unaudited) 1.DESCRIPTION OF BUSINESS Neuronetics, Inc. (the “Company,” “Neuronetics,” “we,” and similar words) believes that mentalhealth is as important as physical health. The Company’s first commercial product, theNeuroStar Advanced Therapy System (the “System”), is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (“TMS”) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of thebrain associated with mood. The System is cleared by the U.S. Food and Drug Administration(the “FDA”) to treat adult patients with major depressive disorder (“MDD”) who have failed toachieve satisfactory improvement from prior antidepressant medication in the current MDDepisode. It is also cleared by the FDA as an adjunct for adults with obsessive-compulsivedisorder (“OCD”) and for adolescent patients aged 15-21 with MDD. It is also cleared by the FDAto decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxietysymptoms (anxious depression). In addition to selling the System and associated treatmentsessions to customers, the Company operates Greenbrook TMS Inc. (“Greenbrook”) treatmentcenters (“Treatment Centers”) across the U.S., offering TMS treatment using the Systems. TheCompany acquired Greenbrook, a provider of mental healthcare services, pursuant to anArrangement Agreement effective as of December 9, 2024 (the “Arrangement”). The System issafe, clinically effective, reproducible and precise, and the Company believes it is supported bythe largest clinical data set of any competing TMS s